时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
The unique design of the NK cells, as they integrate CAR and endogenous receptors that recognize missing and stressed cells, results in the unique ability of engineered NK cells with CAR constructs to locally destroy or kill malignant cells, regardless of whether they downregulate the expression of primary antigens necessary for the recognition of malignant cells by the T cell immune system or express NKG2D, DNAM-1, or natural killer cell activating receptors for mediated cytotoxicity ().；However, the durability of the effects of iPSC-derived CAR-T cells has not yet been fully established ().；The main limitation is no longer redirecting NK cells, but rather whether engineered NK cells will be able to maintain their activity in the hostile environments of hematological systems.
方法
Potency evaluation of cell therapy products may be multi-factorial to include such measurements as live cell counts, therapeutic product expression, genetic modification, and functional bioassays beyond relying on a single analytical output ().；In this regard, release testing for NK cell products may account for both identity and purity and viability, sterility, and contaminant control, as well as functional measurements like target cell kill, while product-specific acceptance criteria need to be established in manufacturing development ().；CAR-T cell therapy has an extensive clinical track record, with several FDA-approved products and durable, sometimes multi-year, remissions in B-cell malignancies, but it continues to face substantial risks of cytokine release syndrome, immune-effector-cell-associated neurotoxicity syndrome, on-target/off-tumor effects, inconsistent therapeutic respon
核心结论
The unique design of the NK cells, as they integrate CAR and endogenous receptors that recognize missing and stressed cells, results in the unique ability of engineered NK cells with CAR constructs to locally destroy or kill malignant cells, regardless of whether they downregulate the expression of primary antigens necessary for the recognition of malignant cells by the T cell immune system or express NKG2D, DNAM-1, or natural killer cell activating receptors for mediated cytotoxicity ().；The graft-versus-host reaction from an iPSC-derived CAR-T cell is likely diminished due to the absence of clonotypic T-cell receptors, and both clinical and preclinical evidence indicates that there is a lower incidence of severe cytokine release syndrome and immune effector cell-associated neurotoxicity when using iPSC-derived CAR-T cells compared to conventional CAR-T therapies. ‖ 结论：These challenges highlight the need for fundamentally new design principles rather than incremental improvements to existing CAR architecture.
局限
In parallel, multiomic technologies are redefining target discovery by capturing tumor heterogeneity at single-cell and spatial resolution, while artificial intelligence integrates these complex datasets into predictive models that guide receptor design and therapeutic optimization.
对本项目的价值
★☆☆☆☆ 炎症衰老是几乎所有慢性老年病的公共通路，也是最有希望做「抗炎但保留免疫」解耦的靶点。
全文来源
PMC JATS 全文（正文 91,372 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Engineering next-generation CAR-NK cells for hematological malignancies: genome editing, synthetic biology, and precision immunotherapy.
- 期刊与标识：Front Genome Ed · PMID 42947991 · DOI 10.3389/fgeed.2026.1943068
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。